PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS 即時價格。貨幣為 USD。

Progenics Pharmaceuticals, Inc.

One World Trade Center
47th Floor
New York City, NY 10007
United States
646-975-2500
http://www.progenics.com

界別Healthcare
行業Biotechnology
全職員工64

高階主管

名稱標題支付行使價出生年份
Mr. Mark R. BakerCEO & Director962.64k1955
Mr. Patrick FabbioSr. VP, CFO & Principal Accounting Officer509.07k1968
Dr. Vivien WongExec. VP of Devel.555.13k1957
Mr. Bryce V. TenbargeSr. VP of Commercial171.84k1973
Melissa DownsSr. Mang. of Investor Relations
截止 2016年12月31日為止計算的金額,現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

公司管治

截至 2018年10月1日 止,Progenics Pharmaceuticals, Inc. 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中:2;董事會:3;股東權利:1;現金賠償:6。

企業管治評分的資料提供: Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險,而 10 分表示較高的管治風險。